Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys 4,005 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 4,005 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $21.02 per share, with a total value of $84,185.10. Following the completion of the acquisition, the director now directly owns 3,012,434 shares in the company, valued at $63,321,362.68. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

NewAmsterdam Pharma Trading Down 1.8 %

NASDAQ:NAMS traded down $0.43 during trading hours on Monday, hitting $23.37. 1,004,047 shares of the company were exchanged, compared to its average volume of 470,541. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -8.99 and a beta of -0.04. The company has a fifty day simple moving average of $22.20 and a 200 day simple moving average of $20.54. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. Equities research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Remove Ads

Analyst Ratings Changes

NAMS has been the subject of several recent research reports. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Scotiabank increased their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Finally, Needham & Company LLC cut their price objective on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $43.33.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in NewAmsterdam Pharma during the 4th quarter valued at $50,000. National Bank of Canada FI purchased a new position in NewAmsterdam Pharma in the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $154,000. Finally, Quarry LP grew its position in NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after purchasing an additional 6,247 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.